These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15853868)

  • 21. Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension.
    de la Sierra A; Munoz A; Arcos E; Lopez JS; Relats J;
    Blood Press Suppl; 2004 Dec; 2():5-10. PubMed ID: 15631277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients.
    Pathak A; Hanon O; Negre-Pages L; Sevenier F;
    Fundam Clin Pharmacol; 2007 Apr; 21(2):199-205. PubMed ID: 17391293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
    Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
    Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihypertensive treatment alters the predictive strength of pulse pressure and other blood pressure measures.
    Greenberg J
    Am J Hypertens; 2005 Aug; 18(8):1033-9. PubMed ID: 16109316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [An AT-II blocker in patients with type II diabetes and arterial hypertension].
    Ametov AS; Demidova TIu; Kosykh SA
    Klin Med (Mosk); 2006; 84(2):50-5. PubMed ID: 16613007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Adjustment of antihypertensive therapy to a generic eprosartan preparation. Results of a non-interventional study].
    Nüdling S; Kahner-Gröne S; Köneke D; Marggraf K; Palissa H
    MMW Fortschr Med; 2010 Oct; 152 Suppl 3():96-101. PubMed ID: 21595153
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey.
    Petrella RJ; Tremblay G; De Backer G; Gill DP;
    Vasc Health Risk Manag; 2014; 10():63-74. PubMed ID: 24493928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients.
    Fogari R; Zoppi A; Ferrari I; Mugellini A; Preti P; Lazzari P; Derosa G
    Horm Metab Res; 2009 Dec; 41(12):893-8. PubMed ID: 19708000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.
    Derosa G; Ragonesi PD; Mugellini A; Ciccarelli L; Fogari R
    Hypertens Res; 2004 Jul; 27(7):457-64. PubMed ID: 15302981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group.
    Gradman AH; Gray J; Maggiacomo F; Punzi H; White WB
    Clin Ther; 1999 Mar; 21(3):442-53. PubMed ID: 10321414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials.
    Xu FY; Yang B; Shi D; Li H; Zou Z; Shi XY
    Eur J Clin Pharmacol; 2012 Feb; 68(2):195-205. PubMed ID: 21881888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension.
    Leu HB; Charng MJ; Ding PY
    Jpn Heart J; 2004 Jul; 45(4):623-35. PubMed ID: 15353873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of eprosartan on mitochondrial membrane potential and H2O2 levels in leucocytes in hypertension.
    Labiós M; Martínez M; Gabriel F; Guiral V; Ruiz-Aja S; Beltrán B; Muñoz A
    J Hum Hypertens; 2008 Jul; 22(7):493-500. PubMed ID: 18385744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A; Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension.
    Breeze E; Rake EC; Donoghue MD; Fletcher AE
    J Hum Hypertens; 2001 Dec; 15(12):857-62. PubMed ID: 11773988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group.
    Hedner T; Himmelmann A
    J Hypertens; 1999 Jan; 17(1):129-36. PubMed ID: 10100104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure.
    Neumann J; Ligtenberg G; Oey L; Koomans HA; Blankestijn PJ
    J Am Soc Nephrol; 2004 Nov; 15(11):2902-7. PubMed ID: 15504943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study).
    Van der Niepen P; Woestenburg A; Brié H; Vancayzeele S; MacDonald K; Denhaerynck K; Lee C; Hermans C; Abraham I
    Ann Pharmacother; 2009 May; 43(5):849-61. PubMed ID: 19351876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.